Friday, December 21, 2018
Loxo Oncology initiates Phase 1/2 clinical trial of LOXO-305
Loxo Oncology announced that it has initiated a Phase 1/2 clinical trial of LOXO-305. LOXO-305 is an investigational, highly selective, non-covalent Bruton’s tyrosine kinase inhibitor specifically designed to address acquired resistance and intolerance in patients previously treated with FDA-approved BTK inhibitors.
https://thefly.com/landingPageNews.php?id=2840475
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.